Zhejiang Hisun Pharmaceutical And Alpharma To Set Up Joint Venture
This article was originally published in PharmAsia News
Zhejiang Hisun Pharmaceutical has signed an MOU with Alpharma API Hong Kong to set up a joint venture that produces and sells vancomycin. With a business term of 30 years, a total of $50 million will be allocated for the investment. Hisun will put up 49 percent of the $24.3 million paid-up capital. An informed source believes Hisun's real motivation in the venture is not to produce the low-profit vancomycin active pharmaceutical ingredients, but rather, to take advantage of Alpharma's international brandname and sales channels to market its own pharmaceutical preparations globally. (Click here for more - Chinese Language)
You may also be interested in...
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.